Special Issue "Advanced Research on Fibromyalgia"
Deadline for manuscript submissions: 31 October 2023 | Viewed by 41446
Interests: fibromyalgia; neuromodulation; spinal cord stimulation; peripheral nerve stimulation; dorsal root ganglion stimulation; peripheral neuropathy; painful diabetic neuropathy; failed back surgery syndrome
Fibromyalgia is a chronic and debilitating disorder that manifests with diffuse musculoskeletal pain, fatigue, psychological distress, poor quality of life, sleep issues, and cognitive dysfunction. The global prevalence of fibromyalgia is high and is estimated to occur in between 2 and 8% of the general population. Diagnosis is primarily established clinically, per the American College of Rheumatology 2010 diagnostic criteria. Importantly, there is a paucity of data supporting the use of diagnostic and treatment-related biomarkers of fibromyalgia.
Treatment is often challenging in patients with fibromyalgia, and current therapeutic options often have limited efficacy. To date, there are only three analgesic medications approved by the United States Food and Drug Administration for the treatment of fibromyalgia, including pregabalin, duloxetine, and milnacipran. These medications typically only offer approximately 30% improvement in pain intensity, which is often unsatisfactory in patients with fibromyalgia who suffer from comorbid psychosocial issues, cognitive dysfunction, and mood disorders.
This Special Issue welcomes all types of manuscripts providing insight on aspects relevant to basic science and clinical research in fibromyalgia. We are interested in a wide range of work, including pathophysiology, diagnostic biomarkers, treatment-related biomarkers, and outcomes-related research in fibromyalgia. Moreover, we are interested in understanding the epigenetics and genetics of fibromyalgia, specifically genetic mutations, and polymorphisms related to fibromyalgia. Finally, data from clinical trials of therapies for fibromyalgia will be highly appreciated. The Special Issue is open for both basic science and clinical studies and will cover original articles, high-quality reviews, and a limited number of pertinent meta-analyses.
Dr. Ryan S. D'Souza
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chronic fatigue syndrome
- myofascial pain syndrome
- diagnostic biomarkers
- biomarkers for predicting treatment response
- chronic pain
- mutations and polymorphisms of genes related to fibromyalgia